Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metaraminol in septic shock patients, a multicenter feasibility trial
ChiCTR2100045337Phase 4Recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of metahydroxylamine in septic shock (2 arms), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: Mean arterial pressure. Started May 2021; status: recruiting.
02
Drugs
metahydroxylamine
03
Conditions
septic shock
Beyond the preview
Go deeper on ChiCTR2100045337.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100045337.